This company is no longer active
IMARA Past Earnings Performance
Past criteria checks 2/6
Key information
-24.42%
Earnings growth rate
66.51%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | n/a |
| Return on equity | 1.65% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal
Oct 13Imara: Potential Liquidation
Sep 29We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Jul 23
We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Sep 09Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?
May 03Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth
Jan 11Revenue & Expenses Breakdown
How IMARA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | 1 | 15 | 19 |
| 30 Sep 22 | 0 | -45 | 16 | 30 |
| 30 Jun 22 | 0 | -54 | 14 | 40 |
| 31 Mar 22 | 0 | -56 | 13 | 42 |
| 31 Dec 21 | 0 | -51 | 13 | 38 |
| 30 Sep 21 | 0 | -49 | 12 | 37 |
| 30 Jun 21 | 0 | -47 | 12 | 36 |
| 31 Mar 21 | 0 | -44 | 11 | 33 |
| 31 Dec 20 | 0 | -49 | 10 | 32 |
| 30 Sep 20 | 0 | -45 | 8 | 29 |
| 30 Jun 20 | 0 | -39 | 7 | 25 |
| 31 Mar 20 | 0 | -34 | 6 | 21 |
| 31 Dec 19 | 0 | -23 | 5 | 19 |
| 30 Sep 19 | 0 | -19 | 4 | 15 |
| 30 Jun 19 | 0 | -16 | 3 | 12 |
| 31 Mar 19 | 0 | -13 | 3 | 10 |
| 31 Dec 18 | 0 | -11 | 2 | 8 |
Quality Earnings: IMRA has a large one-off gain of $34.9M impacting its last 12 months of financial results to December 31 2022.
Growing Profit Margin: IMRA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMRA has become profitable over the past 5 years, growing earnings by -24.4% per year.
Accelerating Growth: IMRA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IMRA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.6%).
Return on Equity
High ROE: IMRA's Return on Equity (1.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/24 22:09 |
| End of Day Share Price | 2023/02/23 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IMARA Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Edward White | H.C. Wainwright & Co. |
| Joseph Schwartz | Leerink Partners LLC |